27 min listen
What My Patients Are Asking: What Is the Lung Inflammation Side Effect Caused by CDK4/6 Inhibitors?
What My Patients Are Asking: What Is the Lung Inflammation Side Effect Caused by CDK4/6 Inhibitors?
ratings:
Length:
7 minutes
Released:
Dec 20, 2019
Format:
Podcast episode
Description
Brian Wojciechowski, M.D., practices medical oncology in Delaware County, Pennsylvania at Riddle, Taylor, and Crozer hospitals and also serves as Breastcancer.org's medical adviser. A native of South Philadelphia, he trained at Temple University School of Medicine and Lankenau Medical Center. Dr. Wojciechowski is a sought-after speaker on the topics of medical ethics and the biology of cancer.
In September 2019, the U.S. Food and Drug Administration released a statement warning that the CDK4/6 inhibitors used to treat breast cancer:
Ibrance (chemical name: palbociclib)
Kisqali (chemical name: ribociclib)
Verzenio (chemical name: abemaciclib)
may cause rare but serious inflammation in the lungs.
Listen to the podcast to hear Dr. Wojciechowski talk about:
how CDK4/6 inhibitors are used to treat breast cancer
why we’re just hearing about this side effect now
the recommendations for anyone being treated with a CDK4/6 inhibitor
In September 2019, the U.S. Food and Drug Administration released a statement warning that the CDK4/6 inhibitors used to treat breast cancer:
Ibrance (chemical name: palbociclib)
Kisqali (chemical name: ribociclib)
Verzenio (chemical name: abemaciclib)
may cause rare but serious inflammation in the lungs.
Listen to the podcast to hear Dr. Wojciechowski talk about:
how CDK4/6 inhibitors are used to treat breast cancer
why we’re just hearing about this side effect now
the recommendations for anyone being treated with a CDK4/6 inhibitor
Released:
Dec 20, 2019
Format:
Podcast episode
Titles in the series (100)
Research Highlights From the San Antonio Breast Cancer Symposium, December 12, 2013: Our experts discuss the latest research out of SABCS 2013 by Breastcancer.org Podcast